Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide (original) (raw)
Figure 5
RI-TATp53C′ Treatment Leads to 50% Long-Term Survival of Mice Bearing Terminal Peritoneal Lymphoma
(A) Treatment of human Namalwa B-cell lymphoma cells with RI-TATp53C′ peptide induces apoptosis. Cells were treated with wild-type or mutant peptide, and DNA content was analyzed by flow cytometry 24 h after peptide addition.
(B) Long-term survival of SCID mice harboring lethal peritoneal Namalwa lymphoma tumor burden after RI-TATp53C′ peptide treatment. Namalwa lymphoma cells were IP injected into SCID mice and allowed to proliferate for 48 h. Mice were then injected 16 times over 20 d with vehicle control (n = 16), 900 μg of wild-type RI-TATp53C′ peptide (n = 12), or 900 μg of mutant peptide (n = 6). Mean survival duration was 35 d for vehicle-treated mice and 33 d for mice receiving mutant peptide, whereas 50% of mice treated with wild-type RI-TATp53C′ peptide remained healthy at 150 d after tumor cell injection.